Post Offer Public Announcement to the Shareholders of

Ranbaxy Laboratories Limited

[Registered office: A-11, Industrial Area, Sahibzada Ajit Singh Nagar, Mohali, Punjab 160 055, India]

This Announcement ('Post Offer PA') is being issued by ICICI Securities Limited, (the 'Manager to the Offer') for and on behalf of Daiichi Sankyo Company, Limited ('Acquirer') pursuant to, inter alia, Regulations 10 and 12 of and as required by under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 as amended ('Regulations') read with observations made vide SEBI letter number CFD/DCR/TO/AG/133560/08 dated August 04, 2008.

This Announcement is in continuation of, and should be read in conjunction with, the Public Announcement published on June 16, 2008 (the "PA") in The Economic Times, Navbharat Times and Punjabi Tribune whereby the Acquirer has made an open offer to the equity shareholders (other than the Sellers) of Ranbaxy Labo atories Limited ("RLL" or the "Target Company") to acquire up to 92,519,126 fully paid-up equity shares of face value of Rs. 5/- each from the remaining shareholders (other than the parties to the Share Purchase and Share Subscription Agreement dated June 11, 2008) of RLL representing up to 20% of the Emerging Voting Capital of RLL (the "Offer") in terms of Regulation 21(1) of the Regulations, at a price of Rs. 737/- per equity share payable in cash subject to the terms and conditions mentioned in the First Corrigendum to Public Announcement published on July 31, 2008 in The Economic Times, Navbharat Times and Punjabi Tribune, the Letter of Offer dispatched to the shareholders of RLL on August 11, 2008 ("Letter of Offer"), the Second Corrigendum to the Public Announcement published on August 11, 2008 in The Economic Times, Navbharat Tir-es and Punjabi Tribune and the Third Corrigendum published on September 23, 2008 in The Economic Times, Navbharat imes and I unjabi Tribune.

The shareholders are requested to note that the Offer formalities have been completed and the details are as under:

1. Name of the Target Company : Ranbaxy Laboratories Limited
2. Name of Acquirer : Daiichi Sankyo Company, Limited
3. Name of Manager to the offer : ICICI Securities Limited
4. Name of the Registrar to the offer : Karvy Computershare Private Limited
5. Offer Details
   a. Date of opening of the offer : August 16, 2008
   b. Date of closure of the offer : September 4, 2008
6. Details of the acquisition:

S. No.	Item	Proposed in the Offer document		Actual	
1	Offer price	Rs. 737		Rs. 737	
2	Share holding of the Acquirer before the PA	Nil		Nil	
3	Shares proposed to be acquired through the SPSSA	129,934,134 shares (34.81% of issued share capital and 28.09% of the Emerging Voting Capital, as on the date of PA) through purchase from promoters and 46,258,063 shares (12.39% of issued share capital and 10% of the Emerging Voting Capital, as on the date of PA) through preferential allotment and 23,834,333 warrants (6.39% of issued share capital and 5.15% of the Emerging Voting Capital, as on the date of PA)		Nil (these shares are yet to be acquired)	
4	Shares acquired in the Open Offer (No. & %)	92,519,126 (24.79% of issued share capital and 20% of the Emerging Voting Capital, as on the date of PA)		92,519,126 (24.79% of issued share capital and 20% of the Emerging Voting Capital, as on the date of PA)	
5	Size of the Open Offer (No. of shares multiplied by offer price per share)	Rs. 68,186,595,862		Rs. 68,186,595,862	
6	Shares acquired after the PA but before 7 working days prior to closure date, if any (No. & %)	Nil		Nil	
7	Post offer shareholding of acquirer (No. & %)	92,519,126 shares (24.79% of issued share capital and 20% of the Emerging Voting Capital, as on the date of PA)		92,519,126 shares (24.79% of issued share capital and 20% of the Emerging Voting Capital, as on the date of PA)	
8	Pre & Post Offer share holding of Public (No. & %)	*Pre Offer*	*Post Offer*	*Pre Offer*	*Post Offer*
		243,301,656 shares (65.19% of issued share capital and 52.59% of the Emerging Voting Capital, as on the date of PA)	150,782,530 shares (40.40% of issued share capital and 32.59% of the Emerging Voting Capital, as on the date of PA)	243,301,656 shares (65.19% of issued share capital and 52.59% of the Emerging Voting Capital, as on the date of PA)	150,782,530 (40.40% of issued shared capital and 32.59% of the Emerging Voting Capital, as on the date of PA)

Notes:

a. As set out in para 2.1.3 of the Letter of Offer, the Sellers have committed to sell to the Acquirer their collective holding of 129,934,134 fully paid-up equity shares of face value of Rs. 5/- each ("Sale Shares") at a price of Rs. 737/- per fully paid-up equity share in cash. The SPSSA also provides for issue and allotment by RLL to the Acquirer of 46,258,063 fully paid-up equity shares of face value Rs 5/- each (the 'Subscription Shares') and the issuance of 23,834,333 warrants of RLL (the 'Warrants'), each Warrant exercisable for one equity share of face value Rs 5/- each of RLL. The subscription price for each Subscription Share and the exercise price of each Warrant is Rs. 737/-.

b. The transfer of Sale Shares and allotment of the Subscription Shares and Warrants is pending, as on the date of this Post Offer PA.

c. The percentages of shareholding, mentioned in the table above, have been calculated based on the shareholding of the Target Company as on the date of the PA (i.e., June 16, 2008) which was 373,237,670 equity shares of face value of Rs 5/- each and has also been calculated on the basis of the Emerging Voting Capital (as defined in Para 7.7 of the Letter of Offer) as on the date of PA which was 462,595,629 equity shares of face value of Rs. 5/- each.

d. The total number of outstanding shares of RLL as on the date of this Post Offer PA is: 374,111,690 equity shares of face value Rs 5/- each

7. Status of the Ranbaxy Laboratories Limited Open Offer Escrow Account: Instructions for release of balance funds will be given shortly
8. Status of investor complaints received: All investor complaints received have been replied to.
9. The payment of consideration under the Offer for accepted shares has been dispatched / credited on October 14, 2008. On account of delay in receipt of certain qualified statutory approvals (as explained in clause 10.6 of the Letter of Offer) interest at the rate of 10% per annum (as directed by SEBI vide letter dated October 7, 2008) from September 20, 2008 till October 14, 2008 (i.e., for 25 days) on the Offer consideration has also been paid to the shareholders who validly tendered their equity shares and whose shares have been accepted under the Offer.

The Acquirer accepts full responsibility for the information contained in this Announcement and their obligations under the Regulations. The terms used but not defined in this Announcement shall have the same meaning as assigned in the PA and the Letter of Offer. This Announcement will also be available on the SEBI website www.sebi.gov.in.

Issued by the Manager to the Offer

For and on behalf of the Acquirer

ICICI Securities

ICICI Securities Limited
ICICI Centre, H.T. Parekh Marg,
Churchgate, Mumbai 400 020, INDIA
Tel: +91 22 2288 2460, Fax: +91 22 2282 6580
Contact Person: Aakash Swaroop
E-mail: projectjewel@iseclid.com

Financial Advisor to the Acquirer

NOMURA

Nomura Securities Co., Ltd.
1-9-1, Nihonbashi, Chuo-ku, Tokyo
103-8011, JAPAN

Place: Mumbai
Date: October 16, 2008